Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.
Saved in:
| Title: | Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. |
|---|---|
| Authors: | Singareeka Raghavendra A; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Damodaran S; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Barcenas CH; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fuqua SA; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA., Layman RM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| Source: | CA: a cancer journal for clinicians [CA Cancer J Clin] 2026 Jan-Feb; Vol. 76 (1), pp. e70055. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0370647 Publication Model: Print Cited Medium: Internet ISSN: 1542-4863 (Electronic) Linking ISSN: 00079235 NLM ISO Abbreviation: CA Cancer J Clin Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1542-4863 |
|---|---|
| DOI: | 10.3322/caac.70055 |
